[Clinical pharmacology in optimization of therapy of lung diseases].
The optimization of the therapy of lung tuberculosis and asthma bronchiale was supported since 1955 by clinical-pharmacological investigations. The prerequisites therefore--using highly specific methods of distribution and quantification in biological material till to the synthesis of 3H-INH and 3H-RMP were introduced step by step. The investigations--in most cases estimations of the nonbiotransformated part of antituberculotic drugs and theophylline had following purposes: security of the necessary dose especially in the case of INH (hereditary INH-polymorphismus), proof of a sufficient permeation of INH and RMP in the tuberculous kidney, control of the usefulness or uselessness of the INH-depot-preparations, relations between the concentration in the serum and dose respectively of the appearance of side effects, estimation of bioavailability and pharmacokinetic parameters during the development of an useful retard-preparation of theophylline.
Iwainsky
H
H
Forschungsinstitut für Lungenkrankheiten und Tuberkulose Berlin-Buch.
Wiesner
B
B
Winsel
K
K
D000995:Antitubercular Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001249:Asthma / Q000097:blood / Q000188:drug therapy*; D001711:Biotransformation; D005000:Ethionamide / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000493:pharmacokinetics / Q000627:therapeutic use; D008657:Metabolic Clearance Rate / Q000502:physiology; D012293:Rifampin / Q000493:pharmacokinetics / Q000627:therapeutic use; D013806:Theophylline / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000188:drug therapy*
D000995:Antitubercular Agents; D013806:Theophylline; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin
Klinische Pharmakologie bei der Therapieoptimierung von Lungenkrankheiten.